StockData
Atossa Therapeutics, Inc. logo

Atossa Therapeutics, Inc. (ATOS) shareholders

ATOSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 6/30
$1.90−0.03 (-1.55%)

Close on Nov 17, 2026Market cap $18.96MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
13.5%
1M of 10M shares
Institutional holders
31
5 new, 7 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only

Shares held by institutions

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of ATOSValueChange% of portfolio
Vanguard Capital Management LLC361,7473.62%$698.17K+12,6510.00%
Ameriprise Financial Inc258,2342.59%$498.39K+3,1000.00%
BlackRock, Inc.164,3581.65%$317.21K+31,1890.00%
Renaissance Technologies LLC132,0431.32%$254.84K+23,0360.00%
Geode Capital Management, LLC92,3820.93%$178.34K−4,6790.00%
UBS Group AG82,6200.83%$159.46K−9,4140.00%
Jane Street Group, LLC56,6020.57%$109.24KNew0.00%
Vanguard Fiduciary Trust Co52,5830.53%$101.49K+3480.00%
Millennium Management LLC46,5080.47%$89.76K−20,2310.00%
State Street Corp39,7610.40%$76.74K–0.00%
Northern Trust Corp20,2490.20%$39.08K+1,0250.00%
Susquehanna International Group, Llp15,5740.16%$30.06KNew0.00%
Morgan Stanley12,3450.12%$23.83K−3,8570.00%
Vanguard Global Advisers, LLC3,0890.03%$5.96K–0.00%
Jones Financial Companies Lllp2,0610.02%$3.88K–0.00%
Royal Bank of Canada1,9940.02%$4.00K+1,3500.00%
MCF Advisors LLC1,0660.01%$2.06KNew0.00%
Osaic Holdings, Inc.5870.01%$1.13K–0.00%
JPMorgan Chase & Co3900.00%$772+70.00%
Rockefeller Capital Management L.P.3330.00%$643−200.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 2026311M13.5%5 / 98 / 70M0M
Q1 2026331M12.4%33 / 00 / 11M0M
Q4 202510M0.0%1 / 00 / 00M0M
Q3 202500M0.0%0 / 00 / 10M0M
Q2 202510M0.0%1 / 00 / 00M0M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

15 funds held ATOS in Q2 2026, 55% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of ATOSValue% of fundAs of
Vanguard Total Stock Market Index Fund256,1372.57%$494.34K0.00%Jun 30, 2026
Columbia Small Cap Value Discovery Fund201,4342.02%$416.97K0.02%Jul 31, 2026
Vanguard Extended Market Index Fund99,0710.99%$191.21K0.00%Jun 30, 2026
Fidelity Extended Market Index Fund46,4090.47%$242.72K0.00%May 31, 2026
Columbia Variable Portfolio - Small Cap Value Discovery Fund36,3830.36%$70.22K0.02%Jun 30, 2026
iShares Micro-Cap ETF29,2030.29%$56.36K0.00%Jun 30, 2026
Fidelity Total Market Index Fund14,3820.14%$75.22K0.00%May 31, 2026
Fidelity Series Total Market Index Fund12,6430.13%$66.12K0.00%May 31, 2026
Vanguard Balanced Index Fund6,5390.07%$12.62K0.00%Jun 30, 2026
Fidelity Nasdaq Composite Index Fund4,2110.04%$22.02K0.00%May 31, 2026
1290 VT Micro Cap Portfolio1,9860.02%$3.83K0.00%Jun 30, 2026
Diversified Equity Alpha Master Portfolio9520.01%$1.84K0.00%Jun 30, 2026
Blackstone Alternative Multi-Strategy Fund-750-0.01%-$1.45K-0.00%Jun 30, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Steven C. QuayPresident & CEO, Director89,5210.90%Mar 31, 2026
Mark James DanielChief Financial Officer63,0000.63%Mar 30, 2026
Heather ReesChief Financial Officer––May 16, 2025
Richard I. SteinhartDirector10,0000.10%May 14, 2026
Jonathan FinnDirector11,6660.12%May 14, 2026
Tessa CiglerDirector10,0000.10%May 14, 2026
Shu-Chih ChenDirector11,4830.12%May 14, 2026
Stephen J. GalliDirector10,0060.10%May 14, 2026
H. Lawrence RemmelDirector12,6830.13%May 14, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Richard I. Steinhart
Director
May 12, 2026Award+10,000––10,000
Stephen J. Galli
Director
May 12, 2026Award+10,000––10,006
Tessa Cigler
Director
May 12, 2026Award+10,000––10,000
H. Lawrence Remmel
Director
May 12, 2026Award+10,000––10,683
Shu-Chih Chen
Director
May 12, 2026Award+10,000––10,000
Jonathan Finn
Director
May 12, 2026Award+10,000––11,666
Steven C. Quay
President & CEO, Director
Mar 27, 2026Award+65,000––88,038
Mark James Daniel
Chief Financial Officer
Mar 26, 2026Award+63,000––63,000
Steven C. Quay
President & CEO, Director
Jan 20, 2026Award+331,674––345,572
Steven C. Quay
President & CEO, Director
Jan 20, 2026Award+325,203––339,101
Steven C. Quay
President & CEO, Director
May 21, 2025Buy+11,239$0.88$9.89K13,898
H. Lawrence Remmel
Director
Mar 26, 2025Buy+10,000$0.70$7.00K10,257
Jonathan Finn
Director
Apr 10, 2024Buy+25,000$1.77$44.25K25,000
Gregory L. Weaver
Former EVP, CFO, & Director
Nov 15, 2023Sale−50,000$0.65$32.50K55
Gregory L. Weaver
EVP & CFO, Director
Jun 20, 2023Buy+50,000$0.97$48.50K50,055
Gregory L. Weaver
Director
Jul 2, 2021Tax withholding−57,084$6.40$365.34K107,497
Gregory L. Weaver
Director
Jul 2, 2021Option exercise+70,000$1.70$119.00K164,581
Gregory L. Weaver
Director
Jul 2, 2021Sale−107,497$5.58$599.83K0
Gregory L. Weaver
Director
Jul 2, 2021Option exercise+45,000$2.52$113.40K94,581
Gregory L. Weaver
Director
Jul 2, 2021Option exercise+4,581$5.64$25.84K4,581
Gregory L. Weaver
Director
Jul 2, 2021Option exercise+45,000$2.38$107.10K49,581
Kyle Guse
CFO, Gen Counsel and Secretary
Nov 15, 2017Buy+8,600$0.34$2.92K8,600
Kyle Guse
CFO, Gen Counsel and Secretary
Nov 15, 2017Buy+1,400$0.34$47610,000
H. Lawrence Remmel
Director
Apr 17, 2017Buy+2,500$0.63$1.58K3,126
H. Lawrence Remmel
Director
Apr 1, 2016Buy+1,500$0.33$49510,900
Steven C. Quay
President & CEO, Director, 10% owner
Mar 9, 2016Buy+15,000$0.37$5.55K4,826,858
Shu-Chih Chen
Director, 10% owner
Mar 9, 2016Buy+15,000$0.37$5.55K4,348,315
Steven C. Quay
President & CEO, Director, 10% owner
Feb 16, 2016Buy+15,000$0.53$7.95K4,811,858
Shu-Chih Chen
Director, 10% owner
Feb 16, 2016Buy+15,000$0.53$7.95K4,333,315
Steven C. Quay
President & CEO, Director, 10% owner
Jan 19, 2016Buy+50,000$0.20$10.00K4,796,858
Shu-Chih Chen
Director, 10% owner
Jan 19, 2016Buy+50,000$0.20$10.00K4,318,315
H. Lawrence Remmel
Director
Jun 12, 2015Buy+5,400$1.30$7.02K9,400
Gregory L. Weaver
Director
May 6, 2014Returned to company−24,510––0
Richard I. Steinhart
Director
May 6, 2014Returned to company−22,728––0
Richard I. Steinhart
Director
Mar 1, 2014Award+22,728––22,728
Gregory L. Weaver
Director
Nov 21, 2013Buy+10,000$2.58$25.80K34,510
Gregory L. Weaver
Director
Oct 10, 2013Award+24,510––24,510
Shu-Chih Chen
Chief Scientific Officer, Director, 10% owner
Oct 1, 2013Sale(10b5-1 plan)−7,265$5.66$41.12K4,268,315
Steven C. Quay
CEO, Director, 10% owner
Oct 1, 2013Sale(10b5-1 plan)−7,265$5.66$41.12K4,268,315
Shu-Chih Chen
Chief Scientific Officer, Director, 10% owner
Jul 18, 2013Gift−5,000––478,543
Shu-Chih Chen
Chief Scientific Officer, Director, 10% owner
Jul 18, 2013Gift−100,000––483,543
Steven C. Quay
Chief Executive Officer, Director, 10% owner
Jul 18, 2013Gift−5,000––478,543
Steven C. Quay
Chief Executive Officer, Director, 10% owner
Jul 18, 2013Gift−100,000––483,543
Shu-Chih Chen
Chief Scientific Officer, Director, 10% owner
May 28, 2013Gift−1,000––583,543
Steven C. Quay
Chief Executive Officer, Director, 10% owner
May 28, 2013Gift−1,000––583,543
Alexander D. Cross
Director
May 15, 2013Buy+500$5.49$2.75K88,866
H. Lawrence Remmel
Director
Jan 8, 2013Buy+1,600$4.20$6.72K2,000
H. Lawrence Remmel
Director
Jan 8, 2013Buy+400$4.10$1.64K400
H. Lawrence Remmel
Director
Jan 8, 2013Buy+2,000$4.05$8.10K2,000

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
5.40%
1M shares short
Days to cover
7.6
At 0M shares a day
Change since last report
-22.9%
From 1M shares
Short volume, 20 days
49.7%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Atossa Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 12,270 shares on Aug 31, 2026 over the last 90 days.

Congress trades

1 trade in Atossa Therapeutics reported by 1 member of the House

MemberTypeTradedAmountFiled
Roger W. Marshall
KS01 · child
BoughtOct 25, 2017$1K–15KAug 6, 2018
285 days late

See a number that looks wrong?